data from 1st cohort of patients in multiple m, page-3

Wow exciting times.

Like this - In all 3 patients, between 80 - 100% of their cancer cells bound PAT-SM6 strongly and specifically.
There was no binding of the antibody to the non-malignant cells confirming the absolute specificity of PAT-SM6 for cancer cells.

and this -

Post inclusion in this trial, 2 out of the 3 patients went on to receive additional chemotherapy due to advancing disease. Both patients had an unexpectedly positive response to drugs that they had previously been resistant to.

This may suggest that PAT-SM6 had an influence on the sensitivity of the malignant cells. It is known from the literature that cancer cells can be converted from resistant
to sensitive when treated with a gents that bind to the cancer-specific form of GRP78, as in the case of PAT-SM6.

Cant wait for second round results.

What an opportunity if these guys get this right.